•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
Is Novartis (NVS) Outperforming Other Medical Stocks This Year?
Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS
3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
Novartis: 3 Key Takeaways for Long-Term Investors
3 Stocks to Watch Following Guidance Upgrades
BioArctic collaborator Novartis terminates agreement
6 dividend stocks for investors who want to cut their exposure to the S&P 500
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
Companies promised AI gains— here's how the payoff showed up in earnings
Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
A pharma giant is moving past one patent cliff — but another is already looming
Novartis AG (NVS) Q3 2026 Earnings Call Transcript
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
What Novartis (NVS) Said on Its Q3 Earnings Call
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
Already premium?